Pharvaris logo

Pharvaris

PHVS | NASDAQ
Chart Builder DCF Calculator
$32.44
-$0.92 (-2.76%)
At close: Nov 16, 2026, 4:00 PM ET
$32.50
+$0.06 (+0.18%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.76%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
19.6
-1.0 pts
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #995/1021 (Top 97%)

Key Statistics

Market Data

Market Cap $2.28B
1D Range
32.43 34.46
52W Range
23.68 38.86

Valuation (TTM)

PE -10.08
PB 7.59
EV/EBITDA -9.34

Valuation (NTM)

Forward PE N/A
Forward PEG 8.02
Price Target $61.00
Loading financial charts...

Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediat...

Sector Healthcare
Industry Biotechnology
Employees 148
IPO Date Feb 4, 2021
Fiscal Year January - December

Latest News

Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?

15 hours ago · zacks.com

Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

4 days ago · globenewswire.com

Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update

4 days ago · globenewswire.com

Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

19 days ago · globenewswire.com

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

25 days ago · benzinga.com

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

1 month ago · globenewswire.com

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

1 month ago · globenewswire.com

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

2 months ago · zacks.com

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

2 months ago · seekingalpha.com

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Earnings

Next Earnings
Apr 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$61.00
Upside
+88.04%
Buy (10)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.